View Item 

Show simple item record

Pre‐eclampsia: a maternal manifestation of a fetal adaptive response?

dc.contributor.authorEspinoza, Jimmyen_US
dc.contributor.authorEspinoza, A. F.en_US
dc.date.accessioned2011-11-10T15:39:38Z
dc.date.available2012-12-03T21:17:30Zen_US
dc.date.issued2011-10en_US
dc.identifier.citationEspinoza, J.; Espinoza, A. F. (2011). "Pre‐eclampsia: a maternal manifestation of a fetal adaptive response?." Ultrasound in Obstetrics & Gynecology 38(4): 367-370. <http://hdl.handle.net/2027.42/87157>en_US
dc.identifier.issn0960-7692en_US
dc.identifier.issn1469-0705en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/87157
dc.publisherJohn Wiley & Sons, Ltd.en_US
dc.titlePre‐eclampsia: a maternal manifestation of a fetal adaptive response?en_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelObstetrics and Gynecologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumThe College of Literature, Science, and the Arts, University of Michigan, Ann Arbor, MI, USAen_US
dc.contributor.affiliationotherDepartment of Obstetrics and Gynecology, William Beaumont Hospital, Royal Oak Michigan and Oakland University, Rochester, MI, USAen_US
dc.contributor.affiliationotherDepartment of Obstetrics and Gynecology, William Beaumont Hospital, Royal Oak Michigan and Oakland University, Rochester, MI, USAen_US
dc.identifier.pmid21936001en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/87157/1/10067_ftp.pdf
dc.identifier.doi10.1002/uog.10067en_US
dc.identifier.sourceUltrasound in Obstetrics & Gynecologyen_US
dc.identifier.citedreferencePage EW. The relation between hydatid moles, relative ischemia of the gravid uterus, and the placental origin of eclampsia. Am J Obstet Gynecol 1939; 37: 291 – 293.en_US
dc.identifier.citedreferenceLevine RJ, Lam C, Qian C, Yu KF, Maynard SE, Sachs BP, Sibai BM, Epstein FH, Romero R, Thadhani R, Karumanchi SA; CPEP Study Group. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med 2006; 355: 992 – 1005.en_US
dc.identifier.citedreferenceMaynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, Libermann TA, Morgan JP, Sellke FW, Stillman IE, Epstein FH, Sukhatme VP, Karumanchi SA. Excess placental soluble fms‐like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003; 111: 649 – 658.en_US
dc.identifier.citedreferenceEspinoza J, Uckele JE, Starr RA, Seubert DE, Espinoza AF, Berry SM. Angiogenic imbalances: the obstetric perspective. Am J Obstet Gynecol 2010; 203: 17.e1 – 8.en_US
dc.identifier.citedreferenceTjoa ML, van Vugt JM, Mulders MA, Schutgens RB, Oudejans CB, van Wijk IJ. Plasma placenta growth factor levels in midtrimester pregnancies. Obstet Gynecol 2001; 98: 600 – 607.en_US
dc.identifier.citedreferenceTidwell SC, Ho HN, Chiu WH, Torry RJ, Torry DS. Low maternal serum levels of placenta growth factor as an antecedent of clinical preeclampsia. Am J Obstet Gynecol 2001; 184: 1267 – 1272.en_US
dc.identifier.citedreferenceChappell LC, Seed PT, Briley A, Kelly FJ, Hunt BJ, Charnock‐Jones DS, Mallet AI, Poston. A longitudinal study of biochemical variables in women at risk of preeclampsia. Am J Obstet Gynecol 2002; 187: 127 – 136.en_US
dc.identifier.citedreferenceTaylor RN, Grimwood J, Taylor RS, McMaster MT, Fisher SJ, North RA. Longitudinal serum concentrations of placental growth factor: evidence for abnormal placental angiogenesis in pathologic pregnancies. Am J Obstet Gynecol 2003; 188: 177 – 182.en_US
dc.identifier.citedreferencePolliotti BM, Fry AG, Saller DN, Mooney RA, Cox C, Miller RK. Second‐trimester maternal serum placental growth factor and vascular endothelial growth factor for predicting severe, early‐onset preeclampsia. Obstet Gynecol 2003; 101: 1266 – 1274.en_US
dc.identifier.citedreferenceKrauss T, Pauer HU, Augustin HG. Prospective analysis of placenta growth factor (PlGF) concentrations in the plasma of women with normal pregnancy and pregnancies complicated by preeclampsia. Hypertens Pregnancy 2004; 23: 101 – 111.en_US
dc.identifier.citedreferenceLevine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, Schisterman EF, Thadhani R, Sachs BP, Epstein FH, Sibai BM, Sukhatme VP, Karumanchi SA. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004; 350: 672 – 683.en_US
dc.identifier.citedreferenceParra M, Rodrigo R, Barja P, Bosco C, Fernandez V, Munoz H, Soto‐Chacón E. Screening test for preeclampsia through assessment of uteroplacental blood flow and biochemical markers of oxidative stress and endothelial dysfunction. Am J Obstet Gynecol 2005; 193: 1486 – 1491.en_US
dc.identifier.citedreferenceChaiworapongsa T, Romero R, Kim YM, Kim GJ, Kim MR, Espinoza J, Bujold E, Gonçalves L, Gomez R, Edwin S, Mazor M. Plasma soluble vascular endothelial growth factor receptor‐1 concentration is elevated prior to the clinical diagnosis of pre‐eclampsia. J Matern Fetal Neonatal Med 2005; 17: 3 – 18.en_US
dc.identifier.citedreferenceMoore Simas TA, Crawford SL, Solitro MJ, Frost SC, Meyer BA, Maynard SE. Angiogenic factors for the prediction of preeclampsia in high‐risk women. Am J Obstet Gynecol 2007; 197: 244.e1 – 8.en_US
dc.identifier.citedreferenceOhkuchi A, Hirashima C, Matsubara S, Suzuki H, Takahashi K, Arai F, Watanabe T, Kario K, Suzuki M. Alterations in placental growth factor levels before and after the onset of preeclampsia are more pronounced in women with early onset severe preeclampsia. Hypertens Res 2007; 30: 151 – 159.en_US
dc.identifier.citedreferencePoon LC, Zaragoza E, Akolekar R, Anagnostopoulos E, Nicolaides KH. Maternal serum placental growth factor (PlGF) in small for gestational age pregnancy at 11(+0) to 13(+6) weeks of gestation. Prenat Diagn 2008; 28: 1110 – 1115.en_US
dc.identifier.citedreferenceErez O, Romero R, Espinoza J, Fu W, Todem D, Kusanovic JP, Gotsch F, Edwin S, Nien JK, Chaiworapongsa T, Mittal P, Mazaki‐Tovi S, Than NG, Gomez R, Hassan SS. The change in concentrations of angiogenic and anti‐angiogenic factors in maternal plasma between the first and second trimesters in risk assessment for the subsequent development of preeclampsia and small‐for‐gestational age. J Matern Fetal Neonatal Med 2008; 21: 279 – 287.en_US
dc.identifier.citedreferencePoon LC, Kametas NA, Maiz N, Akolekar R, Nicolaides KH. First‐trimester prediction of hypertensive disorders in pregnancy. Hypertension 2009; 53: 812 – 818.en_US
dc.identifier.citedreferenceThadhani R, Mutter WP, Wolf M, Levine RJ, Taylor RN, Sukhatme VP, Ecker J, Karumanchi SA. First trimester placental growth factor and soluble fms‐like tyrosine kinase 1 and risk for preeclampsia. J Clin Endocrinol Metab 2004; 89: 770 – 775.en_US
dc.identifier.citedreferenceRana S, Karumanchi SA, Levine RJ, Venkatesha S, Rauh‐Hain JA, Tamez H, Thadhani R. Sequential changes in antiangiogenic factors in early pregnancy and risk of developing preeclampsia. Hypertension 2007; 50: 137 – 142.en_US
dc.identifier.citedreferenceBaumann MU, Bersinger NA, Mohaupt MG, Raio L, Gerber S, Surbek DV. First‐trimester serum levels of soluble endoglin and soluble fms‐like tyrosine kinase‐1 as first‐trimester markers for late‐onset preeclampsia. Am J Obstet Gynecol 2008; 199: 266.e1 – 6.en_US
dc.identifier.citedreferenceRomero R, Nien JK, Espinoza J, Todem D, Fu W, Chung H, Kusanovic JP, Gotsch F, Erez O, Mazaki‐Tovi S, Gomez R, Edwin S, Chaiworapongsa T, Levine RJ, Karumanchi SA. A longitudinal study of angiogenic (placental growth factor) and anti‐angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor‐1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate. J Matern Fetal Neonatal Med 2008; 21: 9 – 23.en_US
dc.identifier.citedreferenceSchmidt M, Dogan C, Birdir C, Kuhn U, Gellhaus A, Kimmig R, Kasimir‐Bauer S. Placental growth factor: a predictive marker for preeclampsia? Gynakol Geburtshilfliche Rundsch 2009; 49: 94 – 99.en_US
dc.identifier.citedreferenceEspinoza J, Romero R, Nien JK, Gomez R, Kusanovic JP, Goncalves LF, Medina L, Edwin S, Hassan S, Carstens M, Gonzalez R. Identification of patients at risk for early onset and/or severe preeclampsia with the use of uterine artery Doppler velocimetry and placental growth factor. Am J Obstet Gynecol 2007; 196: 326.e1 – 13.en_US
dc.identifier.citedreferenceStepan H, Geipel A, Schwarz F, Kramer T, Wessel N, Faber R. Circulatory soluble endoglin and its predictive value for preeclampsia in second‐trimester pregnancies with abnormal uterine perfusion. Am J Obstet Gynecol 2008; 198: 175.e1 – 6.en_US
dc.identifier.citedreferenceWortelboer EJ, Koster MPH, Kuc S, Eijkemans MJC, Bilardo CM, Schielen PCJI, Visser GHA. Longitudinal trends in fetoplacental biochemical markers, uterine artery pulsatility index and maternal blood pressure during the first trimester of pregnancy. Ultrasound Obstet Gynecol 2011; 38: 383 – 388.en_US
dc.identifier.citedreferenceLin S, Shimizu I, Suehara N, Nakayama M, Aono T. Uterine artery Doppler velocimetry in relation to trophoblast migration into the myometrium of the placental bed. Obstet Gynecol 1995; 85: 760 – 765.en_US
dc.identifier.citedreferenceOlofsson P, Laurini RN, Marsal K. A high uterine artery pulsatility index reflects a defective development of placental bed spiral arteries in pregnancies complicated by hypertension and fetal growth retardation. Eur J Obstet Gynecol Reprod Biol 1993; 49: 161 – 168.en_US
dc.identifier.citedreferenceAardema MW, Oosterhof H, Timmer A, van Rooy I, Aarnoudse JG. Uterine artery Doppler flow and uteroplacental vascular pathology in normal pregnancies and pregnancies complicated by pre‐eclampsia and small for gestational age fetuses. Placenta 2001; 22: 405 – 411.en_US
dc.identifier.citedreferenceMadazli R, Somunkiran A, Calay Z, Ilvan S, Aksu MF. Histomorphology of the placenta and the placental bed of growth restricted foetuses and correlation with the Doppler velocimetries of the uterine and umbilical arteries. Placenta 2003; 24: 510 – 516.en_US
dc.identifier.citedreferenceVoigt HJ, Becker V. Doppler flow measurements and histomorphology of the placental bed in uteroplacental insufficiency. J Perinat Med 1992; 20: 139 – 147.en_US
dc.identifier.citedreferenceEspinoza J, Romero R, Mee KY, Kusanovic JP, Hassan S, Erez O, Gotsch F, Than NG, Papp Z, Jai Kim C. Normal and abnormal transformation of the spiral arteries during pregnancy. J Perinat Med 2006; 34: 447 – 458.en_US
dc.identifier.citedreferencePijnenborg R, Vercruysse L, Hanssens M. The uterine spiral arteries in human pregnancy: facts and controversies. Placenta 2006; 27: 939 – 958.en_US
dc.identifier.citedreferenceSandrim VC, Palei AC, Cavalli RC, Araujo FM, Ramos ES, Duarte G, Tanus‐Santos JE. Vascular endothelial growth factor genotypes and haplotypes are associated with pre‐eclampsia but not with gestational hypertension. Mol Hum Reprod 2009; 15: 115 – 120.en_US
dc.identifier.citedreferenceAudibert F, Salomon LJ, Castaigne‐Meary V, Alves K, Frydman R. Selective termination of a twin pregnancy as a treatment of severe pre‐eclampsia. BJOG 2003; 110: 68 – 69.en_US
dc.identifier.citedreferenceHagay ZJ, Levy R, Zalel Y, Weissman A. Single fetal demise in twin gestation resulting in the resolution of severe pre‐eclampsia. Eur J Obstet Gynecol Reprod Biol 1994; 56: 137 – 138.en_US
dc.identifier.citedreferenceSarhanis P, Pugh DH. Resolution of pre‐eclampsia following intrauterine death of one twin. Br J Obstet Gynaecol 1992; 99: 159 – 160.en_US
dc.identifier.citedreferenceDuthie SJ, Walkinshaw SA. Parvovirus associated fetal hydrops: reversal of pregnancy induced proteinuric hypertension by in utero fetal transfusion. Br J Obstet Gynaecol 1995; 102: 1011 – 1013.en_US
dc.identifier.citedreferenceChaiworapongsa T, Espinoza J, Gotsch F, Kim YM, Kim GJ, Goncalves LF, Edwin S, Kusanovic JP, Erez O, Than NG, Hassan SS, Romero R. The maternal plasma soluble vascular endothelial growth factor receptor‐1 concentration is elevated in SGA and the magnitude of the increase relates to Doppler abnormalities in the maternal and fetal circulation. J Matern Fetal Neonatal Med 2008; 21: 25 – 40.en_US
dc.identifier.citedreferenceSchlembach D, Wallner W, Sengenberger R, Stiegler E, Mortl M, Beckmann MW, Lang U. Angiogenic growth factor levels in maternal and fetal blood: correlation with Doppler ultrasound parameters in pregnancies complicated by pre‐eclampsia and intrauterine growth restriction. Ultrasound Obstet Gynecol 2007; 29: 407 – 413.en_US
dc.identifier.citedreferenceSlegel P, Kitagawa H, Maguire MH. Determination of adenosine in fetal perfusates of human placental cotyledons using fluorescence derivatization and reversed‐phase high‐performance liquid chromatography. Anal Biochem 1988; 171: 124 – 134.en_US
dc.identifier.citedreferenceGeorge EM, Cockrell K, Adair TH, Granger JP. Regulation of sFlt‐1 and VEGF secretion by adenosine under hypoxic conditions in rat placental villous explants. Am J Physiol Regul Integr Comp Physiol 2010; 299: R1629 – R1633.en_US
dc.identifier.citedreferenceEspinoza J, Espinoza AF, Power GG. High fetal plasma adenosine: A role for the fetus in preeclampsia? Am J Obstet Gynecol 2011; DOI: 10.1016/j.ajog.2011.06.034.en_US
dc.identifier.citedreferenceTrapani Jr A, Gonçalves LF, Pires MM. Transdermal nitroglycerin in patients with severe pre‐eclampsia with placental insufficiency: effect on uterine, umbilical and fetal middle cerebral artery resistance indices. Ultrasound Obstet Gynecol 2011; 38: 389 – 394.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
10067_ftp.pdf
Size:
62.88KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.